600557 康缘药业
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)5.13310.7929.5927.5686.490
总资产报酬率 ROA (%)3.7467.7156.7815.2824.300
投入资产回报率 ROIC (%)5.10210.5049.0636.8735.626

边际利润分析
销售毛利率 (%)74.54574.26972.09671.90672.899
营业利润率 (%)13.82911.58210.4539.62011.591
息税前利润/营业总收入 (%)13.22510.84510.0419.22210.449
净利润/营业总收入 (%)12.00511.23810.1578.8909.038

收益指标分析
经营活动净收益/利润总额(%)83.17892.17991.82794.374103.978
价值变动净收益/利润总额(%)1.9302.6850.9421.2360.921
营业外收支净额/利润总额(%)1.358-2.325-2.040-6.920-19.359

偿债能力分析
流动比率 (X)2.5002.5172.0941.9781.701
速动比率 (X)2.1772.3001.9021.7461.479
资产负债率 (%)24.36524.40227.39625.67829.285
带息债务/全部投入资本 (%)-2.669-1.6132.9694.5279.736
股东权益/带息债务 (%)-3,732.036-6,149.7953,213.4042,064.423906.257
股东权益/负债合计 (%)299.552298.992255.353278.546232.540
利息保障倍数 (X)-16.635-22.894-49.43941.01014.152

营运能力分析
应收账款周转天数 (天)52.08651.10360.41383.245119.504
存货周转天数 (天)133.55999.581100.950125.488142.622